Pharmaceutical combination preparation comprising phosphodiesterase―5 inhibitors

The present invention controls the size of a tadalafil as, more particularly, the first active component of a pharmaceutical combined preparation containing a phosphonic poda yieseu atmospheres Claim -5 (phosphodiesterase-5) inhibitors of two or more, and by use of surfactants solubility and a dissolution rate and excellent stability to the formulation chemical, bioavailability is improved tadalafil and the second as an active ingredient sildenafil, vardenafil, Udenafil, in Gardena field, mirodenafil and Havana Philo least one PDE is selected from the group consisting of -5 it relates to a combined preparation for, treating erectile dysfunction comprising the inhibitor. Atmospheres of two or more phosphonic poda according to the invention of claim yieseu -5 (phosphodiesterase-5), I is used as the first active ingredient of the pharmaceutical combination preparations containing the inhibitor and the solubility and dissolution characteristics of the tadalafil is soluble drug remarkably improved, existing as tadalafil and sildenafil, vardenafil, Udenafil, in Gardena field, mirodenafil and Havana by including a PDE-5 inhibitor, at least one member selected from the pillow the group consisting of, sildenafil tablets, Cialis Jung in one single dosage form excellent effects worth replacing erectile dysfunction of a single component, that is, causes drug fermentation time (Onset time) fast and efficacy duration longer side effects also significantly reduced, so have a synergistic effect on erectile dysfunction disease, erectile dysfunction, and It may be useful for improvement.